Each year we fund up to 10 projects via our LGR Innovation Award program, which provides pilot funds to enable cutting-edge, CRISPR-based innovation within the laboratories of UCSF and UCB faculty. Examples include, but are not limited to: single-cell sequencing applications, improved lentiviral or RNP-based delivery methods, robust genetic or chemical iPSC differential protocols, development of novel dCas9 fusion proteins for use in screens.
We are accepting proposals for the 2024 Innovation Awards (submissions ends May 15, 2024).
An unprecedented type of joint venture where UCSF, UCB & GSK researchers work side-by-side to brainstorm, design & execute projects. From genome-wide CRISPR screens in disease-relevant cell lines to developing novel CRISPR-based toolsets, each project combines the strengths of industry & academia to deepen our understanding of genetics, discover new targets, and create next-generation technologies.
